MXCT (MaxCyte) Net Income (Continuing Operations): $-35.64 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MXCT MaxCyte Inc MXCT
67 GF Score
Price $1.39
GF Value $2.28
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is MaxCyte Net Income (Continuing Operations)?

MaxCyte MXCT +0.72% 67 Net Income (Continuing Operations) is $-35.64 Mil as of Jun. 2026. GuruFocus rates MXCT with a GF Score™ of 67/100 and a GF Value™ of $2.28 (Possible Value Trap). The stock has 5 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. MaxCyte's Net Income (Continuing Operations) for the three months ended in Jun. 2026 was $-8.87 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 was $-35.64 Mil.

MaxCyte  (NAS:MXCT) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

MaxCyte Net Income (Continuing Operations) Related Terms

MaxCyte Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for MaxCyte's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MaxCyte Net Income (Continuing Operations) Chart

MaxCyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19.08 -23.57 -37.92 -41.06 -44.63

MaxCyte Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.36 -12.42 -9.60 -4.75 -8.87
MXCT
67GF Score
MaxCyte Inc MXCT
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MaxCyte Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of $-35.64 Mil mean?
MaxCyte (MXCT) has a Net Income (Continuing Operations) of $-35.64 Mil as of Jun. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on MaxCyte and its competitors.
Is MaxCyte's Net Income (Continuing Operations) too high?
MaxCyte's current Net Income (Continuing Operations) is $-35.64 Mil. Overall, MaxCyte has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MaxCyte's Net Income (Continuing Operations) compare to STIM and CVRX?
MaxCyte's Net Income (Continuing Operations) of $-35.64 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Medical Devices & Instruments company?
A good Net Income (Continuing Operations) depends on the Medical Devices & Instruments industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on MaxCyte and its competitors. MaxCyte's current Net Income (Continuing Operations) is $-35.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MaxCyte stock overvalued right now?
Based on GuruFocus' analysis, MaxCyte (MXCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.28, compared to a current price of $1.39 — trading 39.1% below its estimated fair value. The current Net Income (Continuing Operations) is $-35.64 Mil. MaxCyte's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For MaxCyte (MXCT), the current Net Income (Continuing Operations) is $-35.64 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MaxCyte (MXCT) Overvalued in 2026?

Based on GuruFocus' analysis, MaxCyte stock appears to be undervalued. The current stock price of $1.39 is trading 39.1% below its estimated GF Value™ of $2.28. GuruFocus considers MaxCyte to be Possible Value Trap.

Key valuation signals for MXCT:

  • Net Income (Continuing Operations): $-35.64 Mil
  • GF Value™: $2.28 vs. price of $1.39 (39.1% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the MXCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MaxCyte Business Description

Other Exchanges MYE0:Germany
Address 9713 Key West Avenue, Suite 400, Rockville, MD, USA, 20850
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
67GF Score

Get the complete analysis for MXCT

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.39
Price
$2.28
GF Value